Price$4.67-0.83 (-15.09%)
2025-09-092025-12-10
News · 26 weeks140%
2025-12-072026-05-31
Mix090d
No activity.
Latest news
25 items- PRENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal CameraTYLER, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue," "ENvue Medical" or the "Company"), a leader in advanced navigation technologies for enteral access, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's patent application titled "Feeding Tube with Electromagnetic Sensor and Camera," Application No. 18/199,059. The allowed patent includes 18 claims covering a feeding tube design that combines electromagnetic navigation with an integrated distal-tip camera, enabling both positional guidance and direct visualization during placement. The allowed claims include innovations such
- PRENvue Medical Signs Strategic Partnership Agreement with U-Deliver for U.S. Distribution of Over-the-Counter Reusable ENFit Syringe LineTYLER, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the signing of a distribution agreement with U-Deliver to distribute ENvue's recently launched over-the-counter reusable ENFit Syringes product line nationwide through non-acute care channels. "We believe that our partnership with U-Deliver is an important step in scaling ENvue's over-the-counter ENFit syringe line and strengthening our presence in the non-acute enteral care marke
- PRENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, CommercialTYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th
- PRENvue Medical Launches Over-the-Counter Reusable ENFit Syringes to Support Feeding and Medication Delivery without a PrescriptionTYLER, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the launch of a line of over-the-counter ENFit Syringes designed to meet both feeding and medication delivery clinical needs. "As care continues to shift beyond the hospital setting, providers and caregivers need reliable, high-quality solutions that support patients throughout the entire care journey," said Doron Besser, MD, CEO of ENvue Medical. "With the launch of our over-the-
- PRENvue Medical Launches Program to Address Patient Pain and Discomfort with Indwelling Nasogastric Tubes Based on Previously Published, Peer-Reviewed Clinical ResearchTYLER, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing on the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the launch of a new development and integration program leveraging vibration-based technology from its NanoVibronix division to address pain and discomfort associated with indwelling nasogastric (NG) tubes. Nasogastric tubes are among the most widely used devices in hospital care and are frequently required to remain in place for extended periods. While clinically essential, indwe
- PRENvue Medical to Ring the Nasdaq Opening Bell on Wednesday, January 14th, 2026TYLER, Texas, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems including enteral access solutions and non-opioid pain management, today announced the Company will ring the Nasdaq Opening Bell at the Nasdaq MarketSite in Times Square, New York, on Wednesday, January 14, 2026. The ceremony will be led by Doron Besser, MD, Chief Executive Officer of ENvue Medical, accompanied by members of the Company's leadership team, the Directors, employees, and key stakeholders who have been essential to the Company's growth and advancement. "Ringin
- INSIDERSEC Form 3 filed by new insider Pionati Pellegrino3 - ENvue Medical, Inc. (0001326706) (Issuer)
- INSIDERSEC Form 3 filed by new insider Johnson David Ian3 - ENvue Medical, Inc. (0001326706) (Issuer)
- SECSEC Form 424B3 filed by NanoVibronix Inc.424B3 - ENvue Medical, Inc. (0001326706) (Filer)
- PRENvue Medical, Formerly NanoVibronix, UroShield® Kit Secures Reimbursement in the UKTYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced that the UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling nationwide prescription reimbursement across the UK. In parallel with this reimbursement milestone, ENvue Medical has secured an initial purchase order from Peak Medical, a leading UK-based distributor specializing in stoma care and urology medical devices with a vast network of hospitals and community settings, reflecting early commercial demand fol
- PRENvue Medical's UroShield® Kit Secures Reimbursement in the UKTYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced that the UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling nationwide prescription reimbursement across the UK. In parallel with this reimbursement milestone, ENvue Medical has secured an initial purchase order from Peak Medical, a leading UK-based distributor specializing in stoma care and urology medical devices with a vast network of hospitals and community settings, reflecting early commercial demand following NHS Dru
- SECNanoVibronix Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - NanoVibronix, Inc. (0001326706) (Filer)
- PRNanoVibronix, Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and 'FEED'New ticker symbol, "FEED" will begin trading on the Nasdaq at the open of the market on December 12, 2025 NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced that it will change its corporate name from NanoVibronix, Inc. to ENvue Medical, Inc., effective December 12, 2025, to better reflect its new strategic direction and primary focus on its ENvue® feeding-tube placement system ("ENvue"). The Company's ticker for its common stock, listed on the Nasdaq Capital Market, will also change to "FEED," which will begin trading under the new symbol beginning with the market open on the sa
- SECAmendment: SEC Form S-3/A filed by NanoVibronix Inc.S-3/A - NanoVibronix, Inc. (0001326706) (Filer)
- SECNanoVibronix Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - NanoVibronix, Inc. (0001326706) (Filer)
- SECNanoVibronix Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - NanoVibronix, Inc. (0001326706) (Filer)
- PRNanoVibronix Issues Letter to ShareholdersENvue® Feeding Tube Placement System Identified as Core Growth Platform Strategic Rebranding and Name Change to Reflect Company's Focus on Multi-Billion-Dollar Enteral-Feeding Market The Company is Considering Strategic Alternatives for Legacy Assets NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today issued a letter to shareholders, highlighting the Company's strategic vision, market opportunities and a rebranding initiative. Dear Shareholders, Since assuming the role of CEO in June 2025, our team has completed a comprehensive review of our operations, technologies and market oppo
- SECSEC Form 10-Q filed by NanoVibronix Inc.10-Q - NanoVibronix, Inc. (0001326706) (Filer)
- SECSEC Form DEF 14A filed by NanoVibronix Inc.DEF 14A - NanoVibronix, Inc. (0001326706) (Filer)
- SECSEC Form PRE 14A filed by NanoVibronix Inc.PRE 14A - NanoVibronix, Inc. (0001326706) (Filer)
- SECNanoVibronix Inc. filed SEC Form 8-K: Leadership Update8-K - NanoVibronix, Inc. (0001326706) (Filer)
- SECAmendment: SEC Form S-3/A filed by NanoVibronix Inc.S-3/A - NanoVibronix, Inc. (0001326706) (Filer)
- PRNanoVibronix Launches "Oscar" Training Aid to Accelerate ENvue Adoption and Unlock New Revenue OpportunitiesTraining platform accelerates onboarding, expands distribution potential and better positions Company for growth NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the launch of Oscar, an advanced training aid, introduced through its ENvue Medical ("ENvue" or "ENvue Medical") division. Oscar is designed to provide clinicians and educators with a standardized, repeatable approach to practicing naso-enteral feeding procedures, addressing a key barrier to adoption of new and current technologies. "We believe that Oscar enhances our ENvue® system offering by providing hospital tra
- SECNanoVibronix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events8-K - NanoVibronix, Inc. (0001326706) (Filer)
- SECSEC Form 424B5 filed by NanoVibronix Inc.424B5 - NanoVibronix, Inc. (0001326706) (Filer)
NAOV FAQ
5 questionsWhat does NanoVibronix Inc. do?
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based...Where does NAOV stock trade?
NanoVibronix Inc. (NAOV) is listed on NASDAQ.What sector and industry is NAOV in?
NanoVibronix Inc. operates in the Health Care sector, Industrial Specialties industry.What companies are similar to NAOV?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare NAOV side-by-side with any of them on Quantisnow.How can I track NAOV on Quantisnow?
Quantisnow aggregates NanoVibronix Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NAOV to receive live email and push alerts on every new disclosure.